Immuneering
Mr. Bookman has served as our General Counsel and Secretary since July 2021. Prior to joining Immuneering, Mr. Bookman served as General Counsel and Secretary of Frequency Therapeutics from September 2019 to July 2021. In this role, he was a member of the Executive Leadership Team and established and led Frequency’s Legal Department as its first in-house attorney. Mr. Bookman also played a key role in Frequency’s initial public offering in October 2019. Prior to his time at Frequency, Michael was an associate at Latham & Watkins LLP, a leading international law firm where he worked on corporate transactional, securities and general business and governance matters, with an emphasis on representing high-growth technology and life sciences companies.
This person is not in any offices
Immuneering
1 followers
Immuneering leverages more than a decade of leadership in bioinformatics to develop new medicines unlikely to be found by traditional drug discovery methods. Its current pipeline of drug candidates is focused on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis.